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Abstract
The microenvironment within solid tumours can influence the metastatic dissemination of tumour cells, and recent
evidence suggests that poorly oxygenated (hypoxic) cells in primary tumours can also affect the survival and
proliferation of metastatic tumour cells in distant organs. Hypoxic tumour cells have been historically targeted
during radiation therapy in attempts to improve loco-regional control rates of primary tumours since hypoxic cells
are known to be resistant to ionizing radiation-induced DNA damage. There are, therefore, a number of
therapeutic strategies to directly target hypoxic cells in primary (and metastatic) tumours, and several compounds
are becoming available to functionally inhibit hypoxia-induced proteins that are known to promote metastasis. This
mini-review summarizes several established and emerging experimental strategies to target hypoxic cells in primary
tumours with potential clinical application to the treatment of patients with tumour metastases or patients at high
risk of developing metastatic disease. Targeting hypoxic tumour cells to reduce metastatic disease represents an
important advance in the way scientists and clinicians view the influence of tumour hypoxia on therapeutic
outcome.
Review
The cellular environment within solid tumours is
increasingly being appreciated as an important limitation
to current cancer therapy. The vasculature within most
solid tumours consists of abnormally formed, poorly
functional blood vessels that are incapable of delivering
sufficient oxygen and nutrients to properly support the
growing tumour mass [1]. Available oxygen is consumed
by rapidly proliferating tumour cells located within 70
to 150 μm of tumour vasculature, thereby limiting the
amount of oxygen that is available to diffuse further into
the tumour tissue. Thus, a proportion of cells in most
t u m o u r s( r a n g i n gf r o m<1 %t o>5 0 % )a r ee x p o s e dt o
relatively low oxygen tensions (pO2 < 10 mmHg, equiva-
lent to < 1.3% O2 in vitro). While reduced oxygen ten-
sions can be lethal for some cells, many tumour cells
a r ea b l et os u r v i v eu n d e rp o o r l yo x y g e n a t e d( h y p o x i c )
conditions. It is well-established that hypoxic tumour
cells are resistant to radiation therapy, but the clinical
impact of hypoxic tumour cells extends beyond the
treatment of localized primary tumours with ionizing
radiation. Hypoxic tumour cells promote tumour
progression and metastasis through a variety of direct
and indirect mechanisms, and hypoxic tumour cells,
therefore, represent a significant impediment to success-
ful cancer therapy.
Patient survival rates are closely associated with the
development of distant metastatic disease [2-4], with an
estimated 90% of cancer-related deaths being attributed
to the metastatic spread of cancer [5,6]. Patients with
primary tumours that contain high proportions of
hypoxic cells have decreased disease-free and overall
survival rates after surgical resection of the primary
tumour [7,8]. The decreased survival is due to the devel-
opment of metastatic disease, suggesting that (unde-
tected) disseminated tumour cells were present in the
patient at the time of surgery. The strong association
between the development of metastatic disease and the
proportion of hypoxic cells in primary tumours suggests
that hypoxic tumour cells promote a more aggressive,
metastatic tumour phenotype. Indeed, hypoxia up-regu-
lates over 80 genes associated with tumour progression,
glycolysis, angiogenesis, and metastasis [9-12] through
the transcriptional activity of the heterodimeric tran-
scription factors hypoxia-inducible factor-1 (HIF-1) and
HIF-2. The importance of hypoxia-induced genes in
promoting metastatic tumour cell invasion and
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dence indicates that secreted hypoxia-induced proteins
such as lysyl oxidase (LOX) [18] can modulate the
microenvironment within distant metastatic target
organs to promote metastatic tumour growth [19]. The
relationship between tumour hypoxia and metastasis
suggests that hypoxic tumour cells are key drivers of the
metastatic process. A wide variety of systemic therapeu-
tic strategies to directly target hypoxic tumour cells
have been clinically tested in combination with radiation
therapy in order to improve loco-regional control of pri-
mary tumours, and there is a clear need for new and
efficacious strategies to treat (or manage) metastatic dis-
ease. We postulate that targeting hypoxic cells in pri-
mary tumours and metastatic tumour foci, as well as
therapeutically inhibiting metastasis-associated proteins
expressed by hypoxic tumour cells, are plausible thera-
peutic strategies to overcome tumour metastases that
warrant further clinical investigation (Figure 1).
Inhibition of hypoxia-induced metastasis-associated
proteins
Hypoxic tumour cells are known to up-regulate a num-
ber of genes that promote metastasis. Consequently, the
therapeutic inhibition or functional targeting of hypoxia-
induced proteins holds promise as a potential strategy
to decrease metastases in patients with hypoxic tumours.
There are a number of small molecule inhibitors of HIF-
1a (the hypoxia-responsive a-subunit of HIF-1) that
have been identified [20,21] including topotecan [22],
YC-1 [23], and PX-478 [24]. While therapeutic inhibi-
tion of HIF-1a has the potential to reduce the expres-
sion of a range of HIF-1 target genes, small molecule
inhibition of transcription factors in vivo is inherently
difficult and the tumour-specificity of HIF-1a inhibition
is not clear. Thus, the inhibition of metastasis-associated
proteins induced by hypoxia may provide more specific
effects on metastatic tumour cell dissemination, meta-
static tumour cell homing to distant organs, and
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Figure 1 Targeting tumour hypoxia to overcome metastasis. Functional inhibition of the HIF-1 transcription factor or hypoxia-inducible
proteins, such as CAIX, LOX, or CXCR4, can affect multiple steps in the metastatic process. A range of hypoxia-activated cytotoxins are also
available to directly target hypoxic cells in primary tumours and in distant tumour metastases.
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tion, and several intriguing targets have been identified
that hold promise for treating metastatic disease.
Carbonic anhydrase-9 (CAIX) is a hypoxia-induced
cell surface protein involved in the regulation of intra-
cellular pH. Therapeutic inhibition of CAIX has recently
been shown to decrease primary tumour growth and
metastasis in pre-clinical breast tumour models [25],
partly by decreasing the ability of hypoxic tumour cells
to adapt to the low extracellular pH found in hypoxic
regions of primary tumours. A number of small mole-
cule inhibitors of CAIX have been developed [26,27],
and cell-surface proteins such as CAIX are attractive
targets because the delivery of CAIX inhibitors is not
limited by penetration of adequate concentrations of
inhibitor into the cell. However, it is worth noting that
(as with any systemic therapeutic) diffusion and delivery
of CAIX inhibitors to hypoxic cells in a poorly vascular-
ized tumour microenvironment is an essential consid-
eration. Nevertheless, the strong link between CAIX
expression and tumour cell hypoxia provides support
for therapeutically targeting CAIX.
LOX is a hypoxia-induced secreted enzyme that cross-
links collagens and elastin in the extracellular matrix
[28,29]. LOX increases breast tumour cell migration and
invasion [18,30,31], and was recently shown to modulate
the recruitment of bone marrow-derived cells to distant
metastatic target organs [19]. The accumulation of bone
marrow-derived cells in distant organs helps to create
the so-called “pre-metastatic niche” that is thought to
represent fertile regions of tissue that promote the
growth of metastatic tumour foci [32,33]. The influence
of hypoxia-induced LOX on two distinct steps in the
metastatic process highlights LOX as an attractive thera-
peutic target for the reduction of metastatic disease. The
inhibition of LOX using b-aminoproprionitrile (bAPN)
or anti-LOX antibodies is effective in pre-clinical models
[18,19], and the development of specific small molecule
inhibitors of LOX is currently underway.
C-X-C chemokine receptor type-4 (CXCR4) is
expressed on a range of normal cell types and is
involved in several physiological processes, including
hematopoiesis, angiogenesis, leukocyte trafficking, and
leukocyte homing [34]. CXCR4 is hypoxia-inducible [35]
and CXCR4 expression on metastatic tumour cells
induces homing of disseminated tumour cells to specific
tissues that express high levels of the CXCR4-specific
ligand stromal cell-derived factor-1a (SDF-1a/CXCL12)
[36]. The importance of CXCR4 in tissue-specific metas-
tasis has resulted in the development of several inhibi-
tors of the CXCR4/SDF-1a axis [37,38]. While the
importance of CXCR4 in several normal tissue processes
may complicate the therapeutic inhibition of this
receptor, CXCR4 remains an extremely attractive thera-
peutic target to disrupt tumour metastasis.
The established role of several hypoxia-induced genes
in promoting metastatic tumour cell dissemination and
growth of metastatic tumour foci underscore the thera-
peutic potential of inhibiting the activity of hypoxia-
induced proteins to reduce tumour metastases. Inhibi-
tion of HIF-1a, CAIX, LOX, or CXCR4 to reduce the
development and growth of tumour metastases repre-
sent rational therapeutic strategies to disrupt the meta-
static process. A complimentary strategy is to utilize
compounds that have been designed to specifically kill
cells at low oxygen tensions, and there are several
hypoxia-activated cytotoxins with exciting potential to
treat tumour metastases.
Hypoxia-activated cytotoxins
Hypoxic tumour cells can be directly targeted using pro-
drugs that are metabolically reduced to cytotoxic agents
in cells at low oxygen tensions [39,40]. The use of
hypoxia-activated cytotoxins to treat metastatic disease
is supported by the detection of hypoxic cells in meta-
static tumour foci in a number of pre-clinical tumour
models. Some groups have shown that micrometastases
smaller than approximately 1 mm
3 can be hypoxic
[41-46], while other groups have found hypoxic tumour
cells develop in metastases as they grow larger than 2 to
3m m
2 in diameter [47]. Clinical data regarding the
hypoxic fraction of metastatic tumours are lacking, due
in large part to infrequent biopsying and subsequent
immunohistochemical analysis of hypoxic cells in
tumour metastases. It is worth noting, however, that
relatively large clinical metastases can contain hypoxic
tumour cells as evidenced by uptake of the radiolabeled
hypoxia marker
18F-EF5 assessed by positron emission
tomography (PET) [48]. Taken together, these pre-clini-
cal and clinical observations indicate that microscopic
and macroscopic metastatic tumour foci can contain
hypoxic tumour cells that are, therefore, directly targeta-
ble using hypoxia-activated cytotoxins.
Tirapazamine (TPZ) [49] is a hypoxia-activated cyto-
toxin that has advanced the furthest in a clinical setting.
In addition to numerous pre-clinical studies demonstrat-
ing efficacy of TPZ in combination with ionizing radia-
tion and chemotherapy [39,40], TPZ has also been
shown to reduce metastases when used as a neoadjuvant
to radiation therapy in mice [50]. After several encoura-
ging Phase I and II clinical trials, tirapazamine was
moved into Phase III trials. However, several Phase III
trials have reported unacceptable toxicity levels and con-
flicting results with respect to the benefit of incorporat-
ing TPZ into standard therapy regimens [51]. Moreover,
a large Phase III clinical trial using TPZ in combination
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improved overall survival or relapse-free survival with
TPZ [52], although several important issues have been
raised with respect to this trial [53,54] that serve as impor-
tant lessons for the future clinical testing of hypoxia-acti-
vated cytotoxins. A common issue with the Phase III TPZ
trials is the failure to pre-select patients with significant
numbers of hypoxic cells in their tumours for treatment
with the hypoxia-activated drug [55]. There are several
methods for detecting and quantifying hypoxic tumour
cells that can be applied in the clinic, and restricting the
use of hypoxia-activated cytotoxins to patients with
hypoxic cells in their tumours is critical to properly evalu-
ate the therapeutic potential of these agents.
Another hypoxia-activated cytotoxin with encouraging
activity is the alkylaminoanthraquinone N-oxide AQ4N
[56,57]. AQ4N has pre-clinical activity in the treatment
of primary tumours, and has been tested in several
Phase I/II trials [40,58-60]. There is also some pre-clini-
cal evidence that AQ4N can reduce metastasis [61]
although it is not clear if the drug reduces metastatic
dissemination by affecting the primary tumour and/or
directly targets hypoxic cells in the tumour metastases.
The 2-nitroimidazole phosphoramidate mustard prodrug
TH-302 is another hypoxia-activated cytotoxin with
impressive pre-clinical activity [62] that has recently
completed a Phase I trial [63]. Although the effect of
TH-302 on tumour metastases has not yet been
reported, TH-302 remains a promising therapeutic for
targeting hypoxic tumour cells.
The 3,5-dinitrobenzamide-2-mustard PR-104 is an
emerging hypoxia-activated pre-prodrug with intriguing
therapeutic potential [64,65]. PR-104 recently completed
a Phase I clinical trial [66] and is currently being tested
in Phase II trials. PR-104 could target tumour metas-
tases due to the presence of hypoxic cells in the meta-
static tumour foci and/or the generation of cytotoxic
PR-104 metabolites by the hypoxia-independent enzy-
matic activity of intracellular a-ketoreductase 1C3 [65]
expressed by many tumour cell types. Regardless, PR-
104 has potential as a hypoxia-activated cytotoxin that
targets metastatic tumour cells in addition to cells in
the primary tumour. Importantly, both TH-302 and PR-
104 display pre-clinical activity when used as single
agents, which sets these compounds apart from earlier
generation hypoxia-activated cytotoxins (such as TPZ)
which demonstrate anti-tumour activity only when used
in combination with radiation or chemotherapy.
Patient selection for therapy designed to target hypoxic
tumour cells
There are several instances where using therapeutic stra-
tegies to target or inhibit the activity of hypoxic tumour
cells to overcome metastasis would be clinically
beneficial. Importantly, the detection and quantification
of hypoxic cells in a primary (and metastatic) tumour
must be used to identify patients most likely to benefit
from therapies designed to target or inhibit hypoxic
tumour cells to treat metastases. There are several
methods used to detect and quantify hypoxia in solid
tumours ranging from physical pO2 probes inserted into
tumours, to evaluating the expression levels of hypoxia-
induced proteins, to administering compounds that bind
in hypoxic tumour cells (for example, pimonidazole [67]
or EF5 [68]) that are quantifiable by immunohistochem-
istry or PET (for example,
18F-EF5 [48]). In addition,
when considering inhibitors of CAIX, LOX, or CXCR4,
selection of patients should be based on examination of
expression levels of these target genes in tumor biopsies
or by PET imaging based on tumour retention of radi-
olabeled antibodies (for example, against CAIX).
Patients presenting with overt metastatic disease could
be selected for hypoxia-based therapy based on the level
of hypoxia in their primary tumours and/or tumour
metastases for direct targeting of hypoxic tumour cells
by hypoxia-activated cytotoxins and to disrupt the meta-
static process by inhibition of hypoxia-induced proteins.
In patients without obvious (detectable) tumour metas-
tases at the time of presentation, the presence of hypoxic
cells in their primary tumour would suggest the patient is
more likely to have undetected disseminated tumour
cells in their system and/or may be at higher risk for
developing metastatic disease after treatment of their pri-
mary tumour [2-4]. These patients would likely benefit
from the incorporation of standard systemic chemother-
apy into the treatment regimen prescribed for their pri-
mary tumour in order to target potential subclinical
metastatic disease, particularly if hypoxia-activated cyto-
toxins are included to target hypoxic cells in the primary
tumour (and micrometastases). Concurrent inhibition of
hypoxia-induced proteins would help to prevent the
further dissemination of metastatic tumour cells and to
limit the development and growth of subclinical tumour
metastases. Patients that experience loco-regional relapse
of their primary tumour after radiation therapy com-
monly develop metastatic disease, and recurrent tumours
tend to be hypoxic. The potential for long-term inhibi-
tion of hypoxia-induced proteins in patients after primary
tumour treatment to prevent the subsequent develop-
ment and growth of tumour metastases is unknown,
although the importance of proteins, such as LOX and
CXCR4, in a number of normal physiological processes
may preclude the long-term use of LOX or CXCR4 inhi-
bitors as prophylactics against metastatic disease.
Conclusions
Rational design of therapeutic strategies to overcome
metastatic disease based on targeting hypoxic tumour
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influence tumour metastasis holds great promise for
improving the treatment of metastatic cancer. Pre-clini-
cal and clinical therapeutic strategies to overcome meta-
static disease based on the presence of hypoxic tumour
cells in primary and metastatic tumours should be pur-
sued to address this important issue.
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